학술논문
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Document Type
Article
Author
Niemann, Carsten U ; Munir, Talha; Moreno, Carol; Owen, Carolyn; Follows, George A; Benjamini, Ohad; Janssens, Ann; Levin, Mark-David; Robak, Tadeusz; Simkovic, Martin; Voloshin, Sergey; Vorobyev, Vladimir; Yagci, Munci; Ysebaert, Loic; Qi, Keqin; Qi, Qianya; Sinet, Pierre; Parisi, Lori; Srinivasan, Srimathi; Schuier, Natasha; Baeten, Kurt; Howes, Angela; Caces, Donne Bennett; Kater, Arnon P
Source
In The Lancet Oncology December 2023 24(12):1423-1433
Subject
Language
ISSN
1470-2045